# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ZyVersa Therapeutics (NASDAQ:ZVSA) reported quarterly losses of $(4.53) per share which missed the analyst consensus estimate o...
ZyVersa Therapeutics shares are trading higher Monday after the company announced the publication of a scientific paper in a pe...
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, or ", ZyVersa", )))), a clinical stage specialty biopharmaceutical company de...
Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabet...